Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of SYR-472 25mg and 50mg Tablets
NCT02372097Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of trelagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Takeda. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for Unchanged SYR-472 and Maximum Observed Plasma Concentration. Started Mar 2015; status: completed.
02
Drugs
trelagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02372097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02372097.